Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Net Cash Flow: 2018-2024

Historic Net Cash Flow for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Dec 2024 value amounting to -$55.0 million.

  • Arcturus Therapeutics Holdings' Net Cash Flow rose 30.43% to -$16.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$56.8 million, marking a year-over-year increase of 24.23%. This contributed to the annual value of -$55.0 million for FY2024, which is 21.94% down from last year.
  • Latest data reveals that Arcturus Therapeutics Holdings reported Net Cash Flow of -$55.0 million as of FY2024, which was down 21.94% from -$45.1 million recorded in FY2023.
  • Arcturus Therapeutics Holdings' Net Cash Flow's 5-year high stood at $391.5 million during FY2020, with a 5-year trough of -$90.4 million in FY2021.
  • For the 3-year period, Arcturus Therapeutics Holdings' Net Cash Flow averaged around -$26.2 million, with its median value being -$45.1 million (2023).
  • Per our database at Business Quant, Arcturus Therapeutics Holdings' Net Cash Flow soared by 1,030.19% in 2020 and then plummeted by 310.61% in 2023.
  • Arcturus Therapeutics Holdings' Net Cash Flow (Yearly) stood at $391.5 million in 2020, then slumped by 123.10% to -$90.4 million in 2021, then skyrocketed by 123.67% to $21.4 million in 2022, then plummeted by 310.61% to -$45.1 million in 2023, then decreased by 21.94% to -$55.0 million in 2024.